Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Novavax Q2 2024 GAAP EPS $0.99 Misses $1.64 Estimate, Sales $415.484M Miss $458.575M Estimate

Author: Benzinga Newsdesk | August 08, 2024 07:42am
Novavax (NASDAQ:NVAX) reported quarterly earnings of $0.99 per share which missed the analyst consensus estimate of $1.64 by 39.63 percent. The company reported quarterly sales of $415.484 million which missed the analyst consensus estimate of $458.575 million by 9.40 percent. This is a 2.11 percent decrease over sales of $424.426 million the same period last year.

Posted In: NVAX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist